Poor Sleep Quality and Associated Factors in Patients with Common Variable Immunodeficiency/Yaygin Degisken Immün Yetmezlik Hastalarinda Kötü Uyku Kalitesi ve Iliskili Faktörler

Objective: This study aimed to examine the sleep quality of common variable immunodeficiency (CVID) patients and to investigate the relationship between sleep quality and depression, anxiety, fatigue, excessive daytime sleepiness and naturel killer (NK) cell counts. Materials and Methods: The study...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of Turkish Sleep Medicine 2022-09, Vol.9 (3), p.214
Hauptverfasser: Yildiz, Eray, Arslan, Sevket, Yildiz, Buket Tugan, Berktas, Deniz Tuncel, Çölkesen, Fatih, Evcen, Recep, Aykan, Filiz Sadi, Kilinç, Mehmet, Aytekin, Gökhan, Aydin, Adem
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective: This study aimed to examine the sleep quality of common variable immunodeficiency (CVID) patients and to investigate the relationship between sleep quality and depression, anxiety, fatigue, excessive daytime sleepiness and naturel killer (NK) cell counts. Materials and Methods: The study included 53 patients followed with CVID diagnosis. To determine sleep quality and conditions associated with sleep quality in CVID patients, Pittsburgh sleep quality index (PSQI), fatigue severity scale (FSS), Hamilton depression scale (HAM-D), Hamilton anxiety scale (HAM-A) and Epworth sleepiness scale (ESS) were used. Results: Fatigue was found in 37 (70%) patients, poor sleep quality in 34 (64%), depression in 20 (38%), anxiety in 16 (30%), and excessive daytime sleepiness in 11 (21%) patients. All patients CVID patients received immunoglobulin replacement therapy: Intravenous immunoglobulin (IVIG) in 37 (72%) and subcutaneous immunoglobulin (SCIG) in 16 (28%) patients. The PSQI, HAM-A, HAM-D and FSS scores of the patients receiving IVIG treatment were higher than those of the patients receiving SCIG treatment (all, p
ISSN:2148-1504
2148-1504
DOI:10.4274/jtsm.galenos.2022.53315